Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders?

QJM: An International Journal of Medicine

Volumn 95, Issue 12, 2002, Pages 787-796

  Timms, P M ^a   Mannan, N ^a   Hitman, G A ^a   Noonan, K ^a   Mills, P G ^b   Syndercombe Court, D ^a   Aganna, E ^a   Price, C P ^a   Boucher, B J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; FOLIC ACID; GELATINASE A; GELATINASE B; GLUCOSE; HOMOCYSTEINE; INSULIN; LIPID; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY BUILD; CHRONIC DISEASE; CIRCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME ANALYSIS; ENZYME REGULATION; FEMALE; FOLLOW UP; GENOTYPE; GLUCOSE TOLERANCE; HUMAN; HYPOTHESIS; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TISSUE INJURY; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 0036924775     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/95.12.787     Document Type: Article

References (33)

1. Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996; 28:45-51.
2. Anand SS, Yusuf S, Vuksan V, Devanesan S, Teo KK, Montague PA, et al. for the SHARE Investigators. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the study of Health Assessment and Risk in Ethnic Groups (SHARE). Lancet 2000; 356:279-84.
3. Barrett-Connor E, Wingard DL. 'Normal' blood glucose and coronary risk. Br Med J 2001; 322:5-6.
4. Grimes DS, Hindle E, Dyer T. Sunlight, cholesterol and coronary heart disease. Q J Med 1996; 89:579-89.
5. Scragg R. Sunlight, vitamin D and cardiovascular disease. In: Crass MF, Aviol LV, eds. Calcium Regulating Hormones and Cardiovascular Function. Boca Raton FL, CRC Press 1994:213-37.
6. Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'? Br J Nutr (Rev) 1998; 79:315-27.
7. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. TIG 1990; 6:121-5.
8. Koenig W. Heart disease and the inflammatory response. Br Med J 2000; 321:187-8.
9. Galis ZS, Sukhova GK, Lrk MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493-503.
10. Kai H, Ikeda H, Yasukawa H. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32:368-72.
11. Dean DD, Schwartz Z, Schmitz J, Muniz OE, Lu Y, Calderon F, Howell DS, Boyan BD. Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect Tissue Res 1996; 35:331-6.
12. Merke M, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, et al. Identification and regulation of 1, 25-dihydroxyvitamin D3 Receptor activity and biosynthesis of 1,25dihydroxyvitamin D3: studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989; 83:1903-15.
13. Sorbi D, Fadly M, Hicks R, Alexander S, Arbeit L. Captopril inhibits the 72kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993; 44:1266-72.
14. Wojtowicz-Praga S. Clinical potential of matrix metalloproteinase inhibitors. Drugs R D 1999; 1:117-29.
15. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJW. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia 1995; 38:1239-45.
16. Hitman GA, Mannan N, McDermott MF, Aganna E, Hales CN, Boucher BJ. Vitamin D receptor polymorphisms influence insulin secretion in Bangladeshi Asians. Diabetes 1998; 47:688-90.
17. Malaban A, Veronikis IE, Holick MF. Redefining vitamin D deficiency. Lancet 1998; 351:805-6.
18. Pocock SJ. Clinical Trials. Chichester, John Wiley, 1983.
19. Ogunkolade BW, Boucher BJ, Prahl JM, Bustin SA, Burrin JM, Noonan K, North BV, Mannan N, McDermott MF, DeLuca HF, Hitman GA. Vitamin D receptor mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity and VDR genotype in Bangladeshi Asians. Diabetes 2002; 51:2294-302.
20. Obeid OA, Mannan N, Perry G, Iles RA, Boucher BJ. Homocysteine and folate in healthy east London Bangladeshis. Lancet 1998; 352:1829-30.
21. Xie X, Ott J. Testing linkage disequilibrium between a disease gene and marker loci. Am J Hum Genet 1993; 53(Suppl. 3):1107.
22. Keaney JF, Vita JA. The value of inflammation for predicting unstable angina. New Eng J Med 2002; 347:55-7.
23. Stephens WP, Klimiuk PS, Berry JL, Mawer FB. Annual high dose vitamin D prophylaxis in Asian Immigrants. Lancet 1981; 2:1199-202.
24. Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, Rom WN. Effect of mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996; 51:306-11.
25. Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, et al. Disease modifying and immunoregulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17:453-6.
26. Reynolds JJ. Immunolocalization of matrix metalloproteinases and TIMP-1 (tissue inhibitor of metalloproteinases) in human gingival tissues from periodontitis patients. J Periodontal Res 1994; 29:118-26.
27. 3 induced differentiation of cultured keratinocytes is accompanied by a PKC-independent regulation of AP-1 DNA binding activity. J Invest Dermatol 2000; 114:1174-9.
28. Schroen DJ, Brinckerhoff CE. Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Expression 1996; 6:197-207.
29. 3 mediated transcriptional repression of the granulocyte-macrophage colony-stimulating factor gene: vitamin D receptor competes for DNA binding with NFAt1 and stabilizes cJun. Mol Cell Biol 1999; 19:1191-9.
30. Wilkinson RJ, Ilewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujerati Asians in west London: a case-control study. Lancet 2000; 355:618-21.
31. Schooten van FJ, Hirvonen A, Maas LM, De Moi BA, Klienjans JCS, Bell DA, et al. Putative susceptibility markers of coronary heart disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J 1998; 12:1409-17.
32. Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, Slama G, Reach G, Selam JL. Taq 1 polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 2002; 45:436-42.
33. Utiger RD. The need for more vitamin D. N Engl J Med 1998; 338:828-9.